A study of the immunohistochemical profile of bladder cancer in neuro-urological patients by the French Association of Urology.

Biomarkers, Tumor / metabolism Carcinogenesis Humans Ki-67 Antigen / metabolism Tumor Suppressor Protein p53 Urinary Bladder Neoplasms / metabolism Urology

Immunohistochemistry Inflammation Squamous cell carcinoma Urinary bladder neoplasms Urinary bladder neurogenic

Journal

World journal of urology

ISSN: 1433-8726

Titre abrégé: World J Urol

Pays: Germany

ID NLM: 8307716

Informations de publication

Date de publication:
Aug 2022

Historique:

received: 22 11 2021

accepted: 13 01 2022

pubmed: 10 2 2022

medline: 16 7 2022

entrez: 9 2 2022

Statut: ppublish

Résumé

To establish whether the expression of markers of cell differentiation (CK7, CK14, CK20, GATA3), apoptosis (p53), proliferation (Ki67, STAG2) and peri-tumoural lymphocytes (CD3, CD8), provides specific information about urothelial carcinogenesis in neuro-urological patients with bladder cancer (NBC). Tissue samples from NBC were retrieved from 15 centres in France and compared to control samples from non neuro-urological patients with bladder cancer (NNBC) and from neuro-urological patients without bladder cancer (NB). The expression of CK7, CK14, CK20, GATA3, p53, Ki67, STAG2, CD3 and CD8 markers was analysed using immunohistochemistry of tissue microarray sections. Overall, tissue samples from 124 patients were included in the study (n = 72 NBC, n = 26 NNBC and n = 26 NB). Muscle invasive bladder cancer (MIBC) was found in 52 NBC patients (72.2%) and squamous cell differentiation in 9 (12.5%). In NBC samples, the expression of CK20 and GATA3 was significantly more frequent in NMIBC compared to MIBC (p = 0.015 and p = 0.004, respectively). CK20 and GATA3 were significantly more expressed in NBC compared to NNBC (p < 0.001 and p = 0.010, respectively). The expression of CK14, Ki67, CD3 and CD8 was significantly more frequent in NBC than in NNBC samples (p = 0.005, p < 0.001, p < 0.001 and p < 0.001, respectively). The expression of CD3 and CD8 was similar in NBC and NB samples. In NBC, markers of basal differentiation, proliferation and peri-tumoural lymphocytes were significantly more expressed compared to NNBC controls. These results suggest the aggressiveness of NBC and the role of chronic inflammation in the carcinogenesis of bladder cancer in neuro-urological patients.

Identifiants

DOI: 10.1007/s00345-022-03942-3 PMID: 35138436

pubmed: 35138436

doi: 10.1007/s00345-022-03942-3

pii: 10.1007/s00345-022-03942-3

doi:

Substances chimiques

Biomarkers, Tumor 0

Ki-67 Antigen 0

Tumor Suppressor Protein p53 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

1939-1947

Subventions

Organisme : French Association of Urology (Association Française d'Urologie-AFU)

ID : Bourse AFU 2020

Organisme : French-speaking Neuro-Urology Study Group (Groupe d'Etude de Neuro-Urologie de Langue Française-GENULF)

ID : Bourse GENULF 2020

Informations de copyright

Références

IARC, Cancer Today (2021) Estimated number of new cases in 2020, worldwide, both sexes, all ages. https://gco.iarc.fr/today/online-analysis-table

Veskimäe E, Espinos EL, Bruins HM, Yuan Y, Sylvester R, Kamat AM, Shariat SF, Witjes JA, Compérat EM (2019) What Is the prognostic and clinical importance of urothelial and nonurothelial histological variants of bladder cancer in predicting oncological outcomes in patients with muscle-invasive and metastatic bladder cancer? A European Association of Urology muscle invasive and metastatic bladder cancer guidelines panel systematic review. Eur Urol Oncol 2:625–642. https://doi.org/10.1016/j.euo.2019.09.003

doi: 10.1016/j.euo.2019.09.003 pubmed: 31601522

Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, Kiemeney L, Lotan Y, Pang K, Silverman DT, Znaor A, Catto JWF (2018) Epidemiology of bladder cancer: a systematic review and contemporary update of risk factors in 2018. Eur Urol 74:784–795. https://doi.org/10.1016/j.eururo.2018.09.001

doi: 10.1016/j.eururo.2018.09.001 pubmed: 30268659

Ismail S, Karsenty G, Chartier-Kastler E, Cussenot O, Compérat E, Rouprêt M, Phé V (2018) Prevalence, management, and prognosis of bladder cancer in patients with neurogenic bladder: a systematic review. Neurourol Urodyn 37:1386–1395. https://doi.org/10.1002/nau.23457

doi: 10.1002/nau.23457 pubmed: 29168217

Welk B, McIntyre A, Teasell R, Potter P, Loh E (2013) Bladder cancer in individuals with spinal cord injuries. Spinal Cord 51:516–521. https://doi.org/10.1038/sc.2013.33

doi: 10.1038/sc.2013.33 pubmed: 23608811

Arslan B, Bozkurt IH, Yonguc T, Vardar E, Degirmenci T, Kozacioglu Z, Gunlusoy B, Minareci S (2015) Clinical features and outcomes of nontransitional cell carcinomas of the urinary bladder: analysis of 125 cases. Urol Ann 7:177–182. https://doi.org/10.4103/0974-7796.150533

doi: 10.4103/0974-7796.150533 pubmed: 25838209 pmcid: 4374255

Castillo-Martin M, Domingo-Domenech J, Karni-Schmidt O, Matos T, Cordon-Cardo C (2010) Molecular pathways of urothelial development and bladder tumorigenesis. Urol Oncol 28:401–408. https://doi.org/10.1016/j.urolonc.2009.04.019

doi: 10.1016/j.urolonc.2009.04.019 pubmed: 20610278

Gaisa NT, Braunschweig T, Reimer N, Bornemann J, Eltze E, Siegert S, Toma M, Villa L, Hartmann A, Knuechel R (2011) Different immunohistochemical and ultrastructural phenotypes of squamous differentiation in bladder cancer. Virchows Arch 458:301–312. https://doi.org/10.1007/s00428-010-1017-2

doi: 10.1007/s00428-010-1017-2 pubmed: 21136076

Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee I-L, Melquist J, Bondaruk J, Majewski T, Zhang S, Pretzsch S, Baggerly K, Siefker-Radtke A, Czerniak B, Dinney CPN, McConkey DJ (2014) Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25:152–165. https://doi.org/10.1016/j.ccr.2014.01.009

doi: 10.1016/j.ccr.2014.01.009 pubmed: 24525232 pmcid: 4011497

Manach Q, Cussenot O, Rouprêt M, Gamé X, Chartier-Kastler E, Reus C, Camparo P, Compérat E, Phé V (2018) Analysis of bladder cancer subtypes in neurogenic bladder tumors. Can J Urol 25:9161–9167

pubmed: 29524970

McConkey DJ, Choi W, Shen Y, Lee I-L, Porten S, Matin SF, Kamat AM, Corn P, Millikan RE, Dinney C, Czerniak B, Siefker-Radtke AO (2016) A prognostic gene expression signature in the molecular classification of chemotherapy-naïve urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: a phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer. Eur Urol 69:855–862. https://doi.org/10.1016/j.eururo.2015.08.034

doi: 10.1016/j.eururo.2015.08.034 pubmed: 26343003

Wang L, Feng C, Ding G, Zhou Z, Jiang H, Wu Z (2013) Relationship of TP53 and Ki67 expression in bladder cancer under WHO 2004 classification. J Buon 18:420–424

pubmed: 23818355

Gönül II, Akyürek N, Dursun A, Küpeli B (2008) Relationship of Ki67, TP53, MDM-2 and BCL-2 expressions with WHO 1973 and WHO/ISUP grades, tumor category and overall patient survival in urothelial tumors of the bladder. Pathol Res Pract 204:707–717. https://doi.org/10.1016/j.prp.2008.03.011

doi: 10.1016/j.prp.2008.03.011 pubmed: 18572327

Wang L, Feng C, Ding G, Ding Q, Zhou Z, Jiang H, Wu Z (2014) Ki67 and TP53 expressions predict recurrence of non-muscle-invasive bladder cancer. Tumour Biol 35:2989–2995. https://doi.org/10.1007/s13277-013-1384-9

doi: 10.1007/s13277-013-1384-9 pubmed: 24241960

Margulis V, Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y (2006) Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res 12:7369–7373. https://doi.org/10.1158/1078-0432.CCR-06-1472

doi: 10.1158/1078-0432.CCR-06-1472 pubmed: 17189409

Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC, Nichols PW, Skinner DG, Jones PA, Cote RJ (1994) Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331:1259–1264. https://doi.org/10.1056/NEJM199411103311903

doi: 10.1056/NEJM199411103311903 pubmed: 7935683

Solomon DA, Kim J-S, Bondaruk J, Shariat SF, Wang Z-F, Elkahloun AG, Ozawa T, Gerard J, Zhuang D, Zhang S, Navai N, Siefker-Radtke A, Phillips JJ, Robinson BD, Rubin MA, Volkmer B, Hautmann R, Küfer R, Hogendoorn PCW, Netto G, Theodorescu D, James CD, Czerniak B, Miettinen M, Waldman T (2013) Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet 45:1428–1430. https://doi.org/10.1038/ng.2800

doi: 10.1038/ng.2800 pubmed: 24121789 pmcid: 3875130

Taylor CF, Platt FM, Hurst CD, Thygesen HH, Knowles MA (2014) Frequent inactivating mutations of STAG2 in bladder cancer are associated with low tumour grade and stage and inversely related to chromosomal copy number changes. Hum Mol Genet 23:1964–1974. https://doi.org/10.1093/hmg/ddt589

doi: 10.1093/hmg/ddt589 pubmed: 24270882

Lelo A, Prip F, Harris BT, Solomon D, Berry DL, Chaldekas K, Kumar A, Simko J, Jensen JB, Bhattacharyya P, Mannion C, Kim J-S, Philips G, Dyrskjøt L, Waldman T (2018) STAG2 is a biomarker for prediction of recurrence and progression in papillary non–muscle-invasive bladder cancer. Clin Cancer Res 24:4145–4153. https://doi.org/10.1158/1078-0432.CCR-17-3244

doi: 10.1158/1078-0432.CCR-17-3244 pubmed: 29954776 pmcid: 6125225

West DA, Cummings JM, Longo WE, Virgo KS, Johnson FE, Parra RO (1999) Role of chronic catheterization in the development of bladder cancer in patients with spinal cord injury. Urology 53:292–297

doi: 10.1016/S0090-4295(98)00517-2

Schlager TA, LeGallo R, Innes D, Hendley JO, Peters CA (2011) B cell infiltration and lymphonodular hyperplasia in bladder submucosa of patients with persistent bacteriuria and recurrent urinary tract infections. J Urol 186:2359–2364. https://doi.org/10.1016/j.juro.2011.07.114

doi: 10.1016/j.juro.2011.07.114 pubmed: 22019034

Yu A, Mansure JJ, Solanki S, Siemens DR, Koti M, Dias ABT, Burnier MM, Brimo F, Kassouf W (2018) Presence of lymphocytic infiltrate cytotoxic T lymphocyte CD3+, CD8+, and immunoscore as prognostic marker in patients after radical cystectomy. PLoS ONE 13:e0205746. https://doi.org/10.1371/journal.pone.0205746

doi: 10.1371/journal.pone.0205746 pubmed: 30308033 pmcid: 6181418